The Globe and Mail reports in its Thursday, July 10, edition that U.S. telehealth platform Hims & Hers Health says it will launch in Canada in the new year to sell generic forms of the blockbuster weight-loss and diabetes drugs Ozempic and Wegovy. The Globe's Chris Hannay writes that it is among the first companies to publicize efforts to take advantage of the Canadian patents on those drugs expiring in January, 2026. Ozempic, which is prescribed for diabetes, and Wegovy, prescribed for weight loss, both contain the active ingredient semaglutide. Generic versions of that ingredient will sell at a fraction of the cost of the brand-name version, which is expected to lift what is already soaring demand for the drugs. Ozempic is produced by Danish drugmaker Novo Nordisk. Ozempic is by far the best-selling drug in Canada. More than $2.5-billion worth of it was sold at retail pharmacies in 2024, according to data broker IQVIA. The number includes markups and dispensing fees. No other drug sold more than $1-billion worth last year. Hims & Hers said Wednesday it will work with another company that is producing the drug. Hims & Hers did not name the manufacturer.